By Stephen Nakrosis
Shares of Alto Neuroscience have fallen to all-time lows in the after-hours market, following news a Phase 2 study of the company's ALTO-100 failed to meet its primary endpoint.
After the bell, the stock had lost 63% and was trading at $5.36. Shares, which debuted in February, recorded their lowest intraday price of $7.91 on Aug. 12.
Alto said its ALTO-100 treatment in patients with major depressive disorder failed to meet its primary endpoint in a Phase 2 study. The treatment didn't demonstrate improvement in depressive symptoms compared to placebo in patients with a memory-based cognitive biomarker, according to Alto.
However, ALTO-100 did demonstrate a favorable safety and tolerability profile, which was consistent with earlier studies, the company said.
Amit Etkin, the company's founder and chief executive officer, said Alto will evaluate the full data set and incorporate learnings set across its platform.
The company said it expects its current cash position to fund planned operations into 2027.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
October 22, 2024 17:31 ET (21:31 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。